2
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
92
Neoplasm Metastasis
6
Prostatic Neoplasms, Castration-Resistant
3
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Neoplasms
2
Genital Diseases, Male
2
Urogenital Neoplasms
1
Stage II Prostate Adenocarcinoma
1
Small Cell Lung Carcinoma
1
Sleep Initiation and Maintenance Disorders
1
Salivary Gland Neoplasms
1
Prostate Cancer With ≤10 Bone Metastases
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Patient Preference
1
Non-metastatic Prostate Cancer
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Neoplasms by Site
1
Neoadjuvant Therapy
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer
1
Metastatic Castrate-sensitive Prostate Cancer
1
Low Risk Prostate Cancer
1
High-Risk and Oligometastatic Prostate Cancer
1
Interventions
Docetaxel
3
Androgen Antagonists
3
enzalutamide
2
darolutamide
2
apalutamide
1
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Hormone-sensitive Prostate Cancer
×
apalutamide
×
Clear all
NCT05901649
2026-05-08
ArtemisPRO
Janssen-Cilag Ltd.
Active not recruiting
504 enrolled